The former Soviet states of the Baltics region are experiencing a serious shortage of drugs, caused by a sharp increase in respiratory diseases in the region, as well as the lack of production capacity and raw materials for meeting growing demand.
According to local analysts, the existing bureaucracy, as well as disruption of logistics chains, which began during the pandemic and intensified during the current Russia and Ukraine conflict, are among the other problems that have led to the shortage of drugs in the Baltics region.
Prior to February 24, 2022, when the invasion of Ukraine was launched, many leading Baltics drugmakers purchased packaging and other raw materials for their production both in Russia and Ukraine. However, currently most of these deliveries are suspended.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze